{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:08:15Z","timestamp":1789117695048,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Cell-free DNA non-invasive prenatal testing (NIPT) is recommended by the American College of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics and Genomics (ACMG) for fetal aneuploidy screening in all pregnancies, yet most testing is performed by centralized reference laboratories. We evaluated whether a whole-genome sequencing (WGS) NIPT assay implemented in a high-complexity clinical laboratory can achieve a performance consistent with established reference laboratories. Methods: We retrospectively analyzed 11,235 evaluable clinical NIPT samples processed in a single Clinical Laboratory Improvement Amendments (CLIA)-certified, College of American Pathologists (CAP)-accredited laboratory using the Illumina VeriSeq NIPT Solution v2, which reports trisomy 21 (T21), trisomy 18 (T18), trisomy 13 (T13), and sex chromosome aneuploidies (SCA). Results were compared with the diagnostic and clinical follow-up; the performance was calculated overall and by maternal age with 95% confidence intervals (CIs). Results: Of 11,318 accessioned samples, 83 (0.73%) were not reportable and excluded. The sensitivity was 100% for all conditions (T21 95% CI 92.1\u2013100%); per-condition specificity exceeded 99.9% (99.81% for any reported aneuploidy overall), with no false-negative results among cases with available follow-ups. Observed positive predictive values (PPVs) were 91.8% (T21), 85.7% (T18), 63.6% (T13), and 79.3% (SCA), consistent with published ranges for this routine, unselected screening population. Conclusions: A high-complexity clinical laboratory can deliver WGS-based NIPT at this level of performance, supporting broader, more timely access to guideline-recommended screening. NIPT remains a screening test, and high-risk results require diagnostic confirmation.<\/jats:p>","DOI":"10.3390\/diagnostics16182936","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:17:42Z","timestamp":1789114662000},"page":"2936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Implementation and Clinical Validation of a Whole-Genome Sequencing Non-Invasive Prenatal Test in a High-Complexity Clinical Laboratory: A Retrospective Analysis of 11,235 Pregnancies"],"prefix":"10.3390","volume":"16","author":[{"given":"Lesley E.","family":"Northrop","sequence":"first","affiliation":[{"name":"Atlanta Women\u2019s Health Group Laboratory, Alpharetta, GA 30022, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Eastway","sequence":"additional","affiliation":[{"name":"Atlanta Women\u2019s Health Group Laboratory, Alpharetta, GA 30022, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Sudhakar","family":"Ravuri","sequence":"additional","affiliation":[{"name":"Atlanta Women\u2019s Health Group Laboratory, Alpharetta, GA 30022, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Genevieve","family":"Fairbrother","sequence":"additional","affiliation":[{"name":"Atlanta Women\u2019s Health Group, Alpharetta, GA 30022, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (ACOG) (2020). Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet. Gynecol., 136, e48\u2013e69.","DOI":"10.1097\/AOG.0000000000004084"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.gim.2022.11.004","article-title":"Noninvasive Prenatal Screening (NIPS) for Fetal Chromosome Abnormalities in a General-Risk Population: An Evidence-Based Clinical Guideline of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Dungan","year":"2023","journal-title":"Genet. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/uog.17484","article-title":"Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Updated Meta-Analysis","volume":"50","author":"Gil","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_4","unstructured":"Illumina, Inc. (2024). VeriSeq NIPT Solution v2 Package Insert (Document No. 1000000078751), Illumina, Inc."},{"key":"ref_5","unstructured":"Illumina, Inc. (2024). VeriSeq NIPT Solution v2 Data Sheet (Document No. 1000000032015), Illumina, Inc."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"McCullough, R.M., Almasri, E.A., Guan, X., Geis, J.A., Hicks, S.C., Mazloom, A.R., Deciu, C., Oeth, P., Bombard, A.T., and Paxton, B. (2014). Non-Invasive Prenatal Chromosomal Aneuploidy Testing-Clinical Experience: 100,000 Clinical Samples. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109173"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa1407349","article-title":"Cell-Free DNA Analysis for Noninvasive Examination of Trisomy","volume":"372","author":"Norton","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"168.e1","DOI":"10.1016\/j.ajog.2023.01.007","article-title":"Cytogenetic Outcomes Following a Failed Cell-Free DNA Screen: A Population-Based Retrospective Cohort Study of 35,146 Singleton Pregnancies","volume":"229","author":"Meng","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.ajog.2022.01.019","article-title":"Cell-Free DNA Screening for Trisomies 21, 18, and 13 in Pregnancies at Low and High Risk for Aneuploidy with Genetic Confirmation","volume":"227","author":"Dar","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Strom, C.M., Anderson, B., Tsao, D., Zhang, K., Liu, Y., Livingston, K., Elzinga, C., Evans, M., Wang, C., and Peters, G. (2017). Improving the Positive Predictive Value of Non-Invasive Prenatal Screening (NIPS). PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0167130"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/GIM.0b013e3182368a0e","article-title":"DNA Sequencing of Maternal Plasma to Detect Down Syndrome: An International Clinical Validation Study","volume":"13","author":"Palomaki","year":"2011","journal-title":"Genet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/pd.4127","article-title":"Noninvasive Prenatal Detection of Sex Chromosomal Aneuploidies by Sequencing Circulating Cell-Free DNA from Maternal Plasma","volume":"33","author":"Mazloom","year":"2013","journal-title":"Prenat. Diagn."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/bdr2.1589","article-title":"National Population-Based Estimates for Major Birth Defects, 2010\u20132014","volume":"111","author":"Mai","year":"2019","journal-title":"Birth Defects Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ajmg.a.32220","article-title":"The Risk of Fetal Loss Following a Prenatal Diagnosis of Trisomy 13 or Trisomy 18","volume":"146A","author":"Morris","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/pd.6580","article-title":"Test Performance and Clinical Utility of Expanded Non-Invasive Prenatal Test: Experience on 71,883 Unselected Routine Cases from One Single Center","volume":"44","author":"Faieta","year":"2024","journal-title":"Prenat. Diagn."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhen, J., Zhang, L., Wang, H., Chen, X., Wang, W., Li, L., and Zhang, Q. (2025). Clinical Experience of Genome-Wide Non-Invasive Prenatal Testing as a First-Tier Screening Test in a Cohort of 59,771 Pregnancies. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0329463"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/gim.2014.3","article-title":"Fetoplacental Mosaicism: Potential Implications for False-Positive and False-Negative Noninvasive Prenatal Screening Results","volume":"16","author":"Grati","year":"2014","journal-title":"Genet. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa1408408","article-title":"Copy-Number Variation and False Positive Prenatal Aneuploidy Screening Results","volume":"372","author":"Snyder","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ajog.2023.11.1240","article-title":"Placental, Maternal, Fetal, and Technical Origins of False-Positive Cell-Free DNA Screening Results","volume":"230","author":"Raymond","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100844","DOI":"10.1016\/j.ajogmf.2022.100844","article-title":"The Accuracy of Prenatal Cell-Free DNA Screening for Sex Chromosome Abnormalities: A Systematic Review and Meta-Analysis","volume":"5","author":"Bussolaro","year":"2023","journal-title":"Am. J. Obstet. Gynecol. MFM"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/18\/2936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:37:20Z","timestamp":1789115840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/18\/2936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":20,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["diagnostics16182936"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16182936","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}